The company's approved products, such as Ameluz and BF-RhodoLED, focus on treating actinic keratoses, a type of skin lesion that can lead to skin cancer. Biofrontera also offers Belixos, a product for the regenerative care of inflamed skin. The company has subsidiaries that handle research and development, manufacturing, and licensing and marketing of its products. Biofrontera is listed on NASDAQ and operates internationally.